DE602005014632D1 - Pyrrol- bzw. imidazolamide zur behandlung von obesitas - Google Patents

Pyrrol- bzw. imidazolamide zur behandlung von obesitas

Info

Publication number
DE602005014632D1
DE602005014632D1 DE602005014632T DE602005014632T DE602005014632D1 DE 602005014632 D1 DE602005014632 D1 DE 602005014632D1 DE 602005014632 T DE602005014632 T DE 602005014632T DE 602005014632 T DE602005014632 T DE 602005014632T DE 602005014632 D1 DE602005014632 D1 DE 602005014632D1
Authority
DE
Germany
Prior art keywords
treatment
imidazolamide
obesitas
bzw
pyrrol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005014632T
Other languages
English (en)
Inventor
Alexander Mayweg
Robert Narquizian
Philippe Pflieger
Stephan Roever
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602005014632D1 publication Critical patent/DE602005014632D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
DE602005014632T 2004-05-10 2005-04-25 Pyrrol- bzw. imidazolamide zur behandlung von obesitas Active DE602005014632D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04102005 2004-05-10
PCT/EP2005/004416 WO2005108393A1 (en) 2004-05-10 2005-04-25 Pyrrole or imidazole amides for treating obesity

Publications (1)

Publication Number Publication Date
DE602005014632D1 true DE602005014632D1 (de) 2009-07-09

Family

ID=34965432

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005014632T Active DE602005014632D1 (de) 2004-05-10 2005-04-25 Pyrrol- bzw. imidazolamide zur behandlung von obesitas

Country Status (14)

Country Link
US (1) US7563910B2 (de)
EP (1) EP1749002B1 (de)
JP (1) JP2007536298A (de)
KR (1) KR100870346B1 (de)
CN (1) CN1950361A (de)
AT (1) ATE432275T1 (de)
AU (1) AU2005240734A1 (de)
BR (1) BRPI0510679A (de)
CA (1) CA2564986A1 (de)
DE (1) DE602005014632D1 (de)
ES (1) ES2324720T3 (de)
MX (1) MXPA06012813A (de)
RU (1) RU2380367C2 (de)
WO (1) WO2005108393A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2368881A1 (de) * 2005-01-10 2011-09-28 University of Connecticut Neue, auf Cannabinoidrezeptoren einwirkende Heteropyrazolanalaoga
CN101384549B (zh) * 2006-02-20 2011-04-13 安斯泰来制药株式会社 吡咯衍生物或其盐
AU2007226673A1 (en) * 2006-03-10 2007-09-20 Jenrin Discovery Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
US8133904B2 (en) * 2007-09-07 2012-03-13 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
MX2010008637A (es) * 2008-02-06 2010-08-30 Daiichi Sankyo Co Ltd Derivado de fenilpirrol novedoso.
JP5918859B2 (ja) 2011-12-02 2016-05-18 フェネックス ファーマシューティカルス アーゲー オーファン核内受容体ＲＡＲに関連するオーファン受容体−ガンマ（ＲＯＲγ、ＮＲ１Ｆ３）活性の調整剤としての、慢性の炎症性疾患および自己免疫性疾患を治療するためのピロロカルボキサミド
JO3215B1 (ar) * 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940418A (en) 1972-04-07 1976-02-24 G. D. Searle & Co. Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2714057B1 (fr) 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5596106A (en) 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2741621B1 (fr) 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2783246B1 (fr) 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
KR100652994B1 (ko) * 1998-09-11 2006-11-30 아방티 파르마 소시에테 아노님 아제티딘 유도체, 이의 제조방법 및 이를 함유하는 약제
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
DK1169312T3 (da) 1999-03-29 2005-01-31 Hoffmann La Roche Glucokinaseaktivatorer
FR2800375B1 (fr) 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
CA2399791A1 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
FR2805810B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
FR2805817B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805818B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
US6566356B2 (en) 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
UA74367C2 (uk) 2000-03-23 2005-12-15 Сольве Фармас'Ютікалз Б.В. ПОХІДНІ 4,5-ДИГІДРО-1Н-ПІРАЗОЛУ, ЩО ВИЯВЛЯЮТЬ АНТАГОНІСТИЧНУ АКТИВНІСТЬ ЩОДО СВ<sub>1</sub>, СПОСІБ ЇХ ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЇЇ ВИГОТОВЛЕННЯ, СПОСІБ ЛІКУВАННЯ ЗАХВОРЮВАНЬ (ВАРІАНТИ)
FR2814678B1 (fr) 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
JP2002210238A (ja) * 2001-01-24 2002-07-30 Sony Computer Entertainment Inc 記録媒体、プログラム、プログラム実行システム及びプログラム実行装置
AU2002319627A1 (en) * 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
MXPA04002438A (es) 2001-09-24 2004-06-29 Bayer Pharmaceuticals Corp Preparacion y uso de derivados de pirroll para el tratamiento de la obesidad.
HN2002000266A (es) 2001-09-24 2003-11-16 Bayer Corp Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad.
AU2003209388A1 (en) * 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators

Also Published As

Publication number Publication date
RU2006143596A (ru) 2008-06-20
AU2005240734A1 (en) 2005-11-17
MXPA06012813A (es) 2007-01-26
BRPI0510679A (pt) 2007-12-26
US20050250769A1 (en) 2005-11-10
CN1950361A (zh) 2007-04-18
ATE432275T1 (de) 2009-06-15
EP1749002B1 (de) 2009-05-27
ES2324720T3 (es) 2009-08-13
RU2380367C2 (ru) 2010-01-27
US7563910B2 (en) 2009-07-21
KR20070009686A (ko) 2007-01-18
WO2005108393A1 (en) 2005-11-17
EP1749002A1 (de) 2007-02-07
KR100870346B1 (ko) 2008-11-25
JP2007536298A (ja) 2007-12-13
CA2564986A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
ATE517882T1 (de) Chinolinderivate
ATE492542T1 (de) Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas
EA200802213A1 (ru) Способы лечения заболеваний крови
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
NO20082096L (no) Azaindol-2-karboksamidderivativer
EA201070422A1 (ru) Производные оксадиазола
SE0303180D0 (sv) Novel compounds
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
SE0302232D0 (sv) Novel Compounds
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
EA201000098A1 (ru) Производные хиназолинамида
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
ATE384058T1 (de) Thiazolderivate
TW200738651A (en) Cyclohexyl sulfonamide derivatives
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
MX2009003981A (es) Agentes moduladores del receptor de calcio.
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
EA201170344A1 (ru) Азаиндольные ингибиторы iap
DE602007006328D1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition